These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 31114181)

  • 1. Relationship of inhaled long-acting bronchodilators with cardiovascular outcomes among patients with stable COPD: a meta-analysis and systematic review of 43 randomized trials.
    Li C; Cheng W; Guo J; Guan W
    Int J Chron Obstruct Pulmon Dis; 2019; 14():799-808. PubMed ID: 31114181
    [No Abstract]   [Full Text] [Related]  

  • 2. Correlation of Inhaled Long-Acting Bronchodilators With Adverse Cardiovascular Outcomes in Patients With Stable COPD: A Bayesian Network Meta-Analysis of Randomized Controlled Trials.
    Wu J; Ye Y; Li C; Zhou W; Chang R
    J Cardiovasc Pharmacol; 2019 Sep; 74(3):255-265. PubMed ID: 31306366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis.
    Rodrigo GJ; Price D; Anzueto A; Singh D; Altman P; Bader G; Patalano F; Fogel R; Kostikas K
    Int J Chron Obstruct Pulmon Dis; 2017; 12():907-922. PubMed ID: 28360514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Cardiovascular and Cerebrovascular Safety of Inhaled Long-Acting Bronchodilators in Patients with Chronic Obstructive Pulmonary Disease: A Population-Based Cohort Study.
    Dong YH; Chang CH; Gagne JJ; Hsu CL; Lai MS
    Pharmacotherapy; 2016 Jan; 36(1):26-37. PubMed ID: 26799347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes.
    Hizawa N
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1093-102. PubMed ID: 26089659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized controlled trials and real-world observational studies in evaluating cardiovascular safety of inhaled bronchodilator therapy in COPD.
    Kardos P; Worsley S; Singh D; Román-Rodríguez M; Newby DE; Müllerová H
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2885-2895. PubMed ID: 27932872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhaled Long-Acting β2-Agonists Do Not Increase Fatal Cardiovascular Adverse Events in COPD: A Meta-Analysis.
    Xia N; Wang H; Nie X
    PLoS One; 2015; 10(9):e0137904. PubMed ID: 26378450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis.
    Rogliani P; Matera MG; Ora J; Cazzola M; Calzetta L
    Int J Chron Obstruct Pulmon Dis; 2017; 12():3469-3485. PubMed ID: 29255354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhaled treatment of COPD: a Delphi consensus statement.
    Ninane V; Corhay JL; Germonpré P; Janssens W; Joos GF; Liistro G; Vincken W; Gurdain S; Vanvlasselaer E; Lehouck A
    Int J Chron Obstruct Pulmon Dis; 2017; 12():793-801. PubMed ID: 28293106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of single inhaler triple therapy vs single inhaler dual therapy or separate triple therapy for the management of chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized controlled trials.
    Lai CC; Chen CH; Lin CYH; Wang CY; Wang YH
    Int J Chron Obstruct Pulmon Dis; 2019; 14():1539-1548. PubMed ID: 31371939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double bronchodilation in chronic obstructive pulmonary disease: a crude analysis from a systematic review.
    Lopez-Campos JL; Calero-Acuña C; Márquez-Martín E; Quintana Gallego E; Carrasco-Hernández L; Abad Arranz M; Ortega Ruiz F
    Int J Chron Obstruct Pulmon Dis; 2017; 12():1867-1876. PubMed ID: 28694697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spotlight on glycopyrronium/formoterol fumarate inhalation aerosol in the management of COPD: design, development, and place in therapy.
    Dhungana S; Criner GJ
    Int J Chron Obstruct Pulmon Dis; 2017; 12():2307-2312. PubMed ID: 28814858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Cardiovascular Risk With Inhaled Long-Acting Bronchodilators in Patients With Chronic Obstructive Pulmonary Disease: A Nested Case-Control Study.
    Wang MT; Liou JT; Lin CW; Tsai CL; Wang YH; Hsu YJ; Lai JH
    JAMA Intern Med; 2018 Feb; 178(2):229-238. PubMed ID: 29297057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aclidinium bromide and formoterol fumarate for the maintenance treatment of chronic obstructive pulmonary disease.
    Haley R; Gupta N; Sethi S
    Expert Rev Clin Pharmacol; 2020 Feb; 13(2):103-113. PubMed ID: 31951778
    [No Abstract]   [Full Text] [Related]  

  • 15. Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide.
    Singh D; Corradi M; Spinola M; Papi A; Usmani OS; Scuri M; Petruzzelli S; Vestbo J
    Int J Chron Obstruct Pulmon Dis; 2017; 12():2917-2928. PubMed ID: 29062229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of Long-Acting Muscarinic Antagonist/Long-Acting β
    Petite SE
    Ann Pharmacother; 2017 Aug; 51(8):696-705. PubMed ID: 28410560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Acting Bronchodilator Initiation in COPD and the Risk of Adverse Cardiopulmonary Events: A Population-Based Comparative Safety Study.
    Suissa S; Dell'Aniello S; Ernst P
    Chest; 2017 Jan; 151(1):60-67. PubMed ID: 27554300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term general and cardiovascular safety of tiotropium/olodaterol in patients with moderate to very severe chronic obstructive pulmonary disease.
    Buhl R; Magder S; Bothner U; Tetzlaff K; Voß F; Loaiza L; Vogelmeier CF; McGarvey L
    Respir Med; 2017 Jan; 122():58-66. PubMed ID: 27993292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The safety of dual bronchodilation on cardiovascular serious adverse events in COPD.
    Rogliani P; Ora J; Matera MG; Cazzola M; Calzetta L
    Expert Opin Drug Saf; 2018 Jun; 17(6):589-596. PubMed ID: 29716427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of Cardiovascular and Cerebrovascular Events in COPD Patients Treated With Long-Acting β
    Samp JC; Joo MJ; Schumock GT; Calip GS; Pickard AS; Lee TA
    Ann Pharmacother; 2017 Nov; 51(11):945-953. PubMed ID: 28677404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.